Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
BCRX BioCryst Pharmaceuticals	$8.96 -4.3%	$9.98	$6.02 ▼ $12.50	$1.96B	1.1	3.03 million shs	5.12 million shs
DTIL Precision BioSciences	$4.20 -2.3%	$4.99	$3.61 ▼ $11.09	$47.68M	1.48	223,267 shs	158,073 shs
TARA Protara Therapeutics	$3.03 +5.2%	$3.30	$1.60 ▼ $10.48	$111.12M	1.34	793,855 shs	727,000 shs
TBIO Telesis Bio	$0.30 +200.0%	$0.20	$0.01 ▼ $6.17	$541K	0.96	6,759 shs	2,028 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	-45.71%	-92.49%
BCRX BioCryst Pharmaceuticals	0.00%	-7.33%	-12.77%	+24.80%	+51.46%
DTIL Precision BioSciences	0.00%	-10.23%	-11.52%	-9.85%	-55.81%
TARA Protara Therapeutics	0.00%	-5.57%	-6.49%	-32.39%	+38.46%
TBIO Telesis Bio	0.00%	+200.00%	+500.00%	+1.66%	-91.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.1847 of 5 stars	3.8	0.0	0.0	0.6	0.0	0.0
BCRX BioCryst Pharmaceuticals	4.4427 of 5 stars	4.4	2.0	4.2	1.9	1.7	0.6
DTIL Precision BioSciences	4.5546 of 5 stars	3.5	3.0	4.6	2.9	1.7	1.3
TARA Protara Therapeutics	2.1437 of 5 stars	3.6	1.0	0.0	3.1	0.8	0.6
TBIO Telesis Bio	0.1932 of 5 stars	0.0	3.0	0.0	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.89	88.49% Upside
DTIL Precision BioSciences	3.00	Buy	$47.00	1,019.05% Upside
TARA Protara Therapeutics	3.14	Buy	$20.50	576.57% Upside
TBIO Telesis Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TBIO, BCRX, TARA, DTIL, and APTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/29/2025	BCRX BioCryst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$20.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
BCRX BioCryst Pharmaceuticals	$450.71M	4.16	N/A	N/A	($2.30) per share	-3.90
DTIL Precision BioSciences	$68.70M	0.68	N/A	N/A	$6.87 per share	0.61
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A
TBIO Telesis Bio	$225.09M	0.00	N/A	N/A	$0.14 per share	2.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	1.87	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
DTIL Precision BioSciences	$7.17M	-$2.01	N/A	N/A	N/A	-42.99%	-69.26%	-29.30%	7/30/2025 (Estimated)
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-36.37%	-33.29%	8/5/2025 (Estimated)
TBIO Telesis Bio	-$47.72M	-$28.20	N/A	∞	N/A	-336.59%	N/A	-61.89%	8/5/2025 (Estimated)

Latest TBIO, BCRX, TARA, DTIL, and APTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A
TBIO Telesis Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
DTIL Precision BioSciences	0.45	6.62	6.62
TARA Protara Therapeutics	N/A	18.03	18.03
TBIO Telesis Bio	N/A	1.23	1.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
BCRX BioCryst Pharmaceuticals	85.88%
DTIL Precision BioSciences	37.99%
TARA Protara Therapeutics	38.13%
TBIO Telesis Bio	37.63%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
BCRX BioCryst Pharmaceuticals	4.80%
DTIL Precision BioSciences	4.00%
TARA Protara Therapeutics	12.50%
TBIO Telesis Bio	24.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
DTIL Precision BioSciences	200	11.09 million	10.64 million	No Data
TARA Protara Therapeutics	30	38.58 million	33.76 million	Optionable
TBIO Telesis Bio	200	1.80 million	1.36 million	Optionable

TBIO, BCRX, TARA, DTIL, and APTO Headlines

Recent News About These Companies

Telesis Bio Inc (TBIO) Stock Forums - Investing.com

June 29 at 10:26 AM | investing.com

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

May 28, 2025 | finance.yahoo.com

Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

March 20, 2025 | finance.yahoo.com

Telesis Bio: Q3 Earnings Snapshot

November 8, 2024 | timesunion.comT

Telesis Bio Announces Departure of Chief Legal Officer

October 25, 2024 | markets.businessinsider.com

Telesis Bio Shares Double After News of Beckman Coulter Life Sciences Collaboration

September 27, 2024 | marketwatch.com

What's Going On With Telesis Bio Shares Thursday?

September 27, 2024 | msn.com

Telesis Bio Inc (TBIO) Stock: More Strategic Than Meets the Eye

September 27, 2024 | bovnews.comB

Telesis Bio Stock Is Soaring Wednesday: What's Going On?

September 26, 2024 | msn.com

Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

September 25, 2024 | globenewswire.com

The TBIO Conundrum: Why Telesis Bio Inc’s Stock Is Making Headlines Again

September 21, 2024 | bovnews.comB

Telesis Bio Inc (TBIO) Stock: Greater Than Its Current Valuation?

September 19, 2024 | bovnews.comB

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

September 10, 2024 | globenewswire.com

Telesis Bio Names CEO Eric Esser as Chair After Five Board Members Resign

August 30, 2024 | marketwatch.com

Telesis Bio Inc

August 15, 2024 | money.usnews.com

TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q2 2024

August 7, 2024 | msn.com

Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

August 7, 2024 | finance.yahoo.com

Telesis Bio (NASDAQ:TBIO) Stock, Short Interest Report

July 31, 2024 | benzinga.com

TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q1 2024

May 10, 2024 | investorplace.com

Telesis Bio Reports First Quarter 2024 Financial Results

May 9, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBIO, BCRX, TARA, DTIL, and APTO Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.96 -0.40 (-4.27%)

As of 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Precision BioSciences NASDAQ:DTIL

$4.20 -0.10 (-2.33%)

As of 04:00 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Protara Therapeutics NASDAQ:TARA

$3.03 +0.15 (+5.21%)

As of 04:00 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Telesis Bio NASDAQ:TBIO

$0.30 +0.20 (+200.00%)

As of 06/27/2025 12:56 PM Eastern

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time